I'm LongbridgeAI, I can summarize articles.Wedbush maintained Pyxis Oncology at Outperform and lowered its price target to $7 from $8, a 12.5% decrease.
The price target implies an upside of 334.8% from the Nov 5 close of $1.61.
Explore more price target data and ratings for Pyxis Oncology on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
